Table 2. Risk of outcomes during follow up period in propensity score matched cohort of statin users in comparison to active comparators.
| PS-Overall Cohort (Primary analysis) | PS-Diabetes Prevalent Cohort | |||||||
|---|---|---|---|---|---|---|---|---|
| Statin users N (%) N = 81,146 | Active comparators N (%) N = 81,146 | OR (95%CI) | P-value | Statin users N (%) N = 51,370 | Active comparators N (%) N = 51,370 | OR (95%CI) | P-value | |
| Primary outcomes | ||||||||
| Renal disease progression composite outcome | 7,692 (9.5) | 6,724 (8.3) | 1.16 (1.12–1.20) | <0.001 | 4,980 (9.7) | 4,479 (8.7) | 1.12 (1.08–1.17) | <0.001 |
| Incident Diabetes with ophthalmic manifestations | 2,149 (2.7) | 1,602 (2.0) | 1.35 (1.27–1.44) | <0.001 | 1,931 (3.8) | 1,485 (2.9) | 1.31 (1.22–1.41) | <0.001 |
| Incident Diabetes with neurological manifestations | 5,422 (6.7) | 4,582 (5.7) | 1.19 (1.15–1.25) | <0.001 | 3,766 (7.3) | 3,593 (7.0) | 1.05 (1.00–1.10) | 0.04 |
| Secondary outcomes | ||||||||
| Components of the composite renal disease progression outcome | ||||||||
| Doubling mean serum creatinine | 1,580 (2.0) | 1,520 (1.9) | 1.04 (0.97–1.12) | 0.28 | 1,143 (2.2) | 1,083 (2.1) | 1.06 (0.97–1.15) | 0.20 |
| Incident Stage 5 CKD | 729 (0.9) | 636 (0.8) | 1.14 (1.03–1.28) | 0.01 | 542 (1.1) | 464 (0.9) | 1.17 (1.03–1.33) | 0.01 |
| Incident renal replacement therapy | 805 (1.0) | 728 (0.9) | 1.11 (1.0–1.22) | <0.05 | 547 (1.1) | 473 (0.9) | 1.16 (1.02–1.31) | 0.02 |
| Incident diabetic nephropathy | 1,209 (1.5) | 967 (1.2) | 1.25 (1.15–1.37) | <0.001 | 1,018 (2.0) | 800 (1.6) | 1.28 (1.16–1.40) | <0.001 |
| Incident CKD | 6,011 (7.4) | 5,053 (6.2) | 1.20 (1.16–1.25) | <0.001 | 3,795 (7.4) | 3,248 (6.3) | 1.18 (1.13–1.24) | <0.001 |
| Change in mean creatinine (mg/dL) from the baseline period to the last year of follow up: | ||||||||
| Mean (SD) | 0.069 (0.612) | 0.063 (0.602) | - | 0.05 | 0.092 (0.614) | 0.081 (0.606) | 0.004 | |
| Median (interquartile) * | 0.00 (-0.1, 0.12) | 0.00 (-0.1, 0.13) | - | 0.007 | 0.01 (-0.1, 0.13) | 0.01 (-0.1, 0.15) | 0.02 | |
| - | ||||||||
| Negative control outcome | ||||||||
| Chronic obstructive pulmonary diseases | 23,544 (29.0) | 23,604 (29.1) | 1.0 (0.98–1.02) | 0.77 | 12,732 (24.8) | 12,754 (24.8) | 1.00 (0.97–1.03) | 0.87 |
| Suicide and intentional self-inflicted injury | 2,796 (3.5) | 2,838 (3.5) | 0.98 (0.93–1.04) | 0.57 | 1,265 (2.5) | 1,283 (2.5) | 1.01 (0.94–1.10) | 0.72 |
| Post-hoc outcome | ||||||||
| Any retinopathy & its complications | 5,079 (6.3) | 4,264 (5.3) | 1.20 (1.15–1.26) | <0.001 | 3,613 (7.0) | 4,219 (8.2) | 1.18 (1.13–1.24) | <0.001 |
CKD = Chronic kidney diseases; PS = Propensity score
* Using Wilcoxon rank-sum test